Pneumonia prevention

	Pneumonia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pneumonia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
Diagnostic Algorithm
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
Other Imaging Findings
Treatment
Medical Therapy
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pneumonia prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pneumonia prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pneumonia prevention
CDC onPneumonia prevention
Pneumonia prevention in the news
Blogs on Pneumonia prevention
Directions to Hospitals Treating Pneumonia
Risk calculators and risk factors for Pneumonia prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]

Overview

There are several ways to prevent infectious pneumonia. Appropriately treating underlying illnesses (such as AIDS), smoking cessation, vaccination against pneumococcal, and influenza are the commonly used methods.

Prevention

General Considerations

There are several ways to prevent infectious pneumonia. Appropriately treating underlying illnesses (such as AIDS) can decrease a person's risk of pneumonia.
Smoking cessation is important not only because it helps to limit lung damage, but also because cigarette smoke interferes with many of the body's natural defenses against pneumonia.
Research shows that there are several ways to prevent pneumonia in newborn infants. Testing pregnant women for Group B Streptococcus and chlamydia trachomatis, and then giving antibiotic treatment if needed, reduces pneumonia in infants. Suctioning the mouth and throat of infants with meconium-stained amniotic fluid decreases the rate of aspiration pneumonia.
Vaccination is important for preventing pneumonia in both children and adults. Vaccinations against haemophilus influenzae and streptococcus pneumoniae in the first year of life have greatly reduced their role in pneumonia in children.
Vaccinating children against streptococcus pneumoniae has also led to a decreased incidence of these infections in adults because many adults acquire infections from children. A vaccine against streptococcus pneumoniae is also available for adults. ^[1]. Influenza vaccines should be given yearly to the same individuals who receive vaccination against streptococcus pneumoniae. In addition, health care workers, nursing home residents, and pregnant women should receive the vaccine.^[2]
When an influenza outbreak is occurring, medications such as amantadine, rimantadine, zanamivir, and oseltamivir can help prevent influenza.^[3]^,^[4]

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. ^[5] (DO NOT EDIT)

“

Pneumococcal Vaccine

Route of administration - Intramuscular injection
Type of vaccine - Pneumococcal polysaccharide vaccine
Recommended groups - All persons > 65 years of age, high-risk persons 2–64 years of age, current smokers
Specific high-risk indications for vaccination - Chronic cardiovascular, pulmonary, renal, or liver disease, diabetes mellitus, cerebrospinal fluid leaks, alcoholism, asplenia, immunocompromising conditions/medications, native Americans and Alaska natives, long-term care facility residents Residence
Revaccination schedule - One-time revaccination after 5 years for (1) adults > 65 years of age, if the first dose is received before age 65 years; (2) persons with asplenia; and (3) immunocompromised persons.

Inactivated influenza vaccine

Route of administration - Intramuscular injection
Type of vaccine - killed virus
Recommended groups - All persons > 50 years of age, High-risk persons 6 months–49 years of age, household contacts of high-risk

persons, health care providers, children 6–23 months of age

Specific high-risk indications for vaccination -Chronic cardiovascular or pulmonary disease (including asthma), Chronic metabolic disease (including diabetes mellitus), Renal dysfunction, Hemoglobinopathies, Immunocompromising conditions/medications, Compromised respiratory function or increased aspiration risk, pregnancy, aspirin therapy in persons < 18 years of age
Revaccination schedule - Annual revaccination

Live Attenuated Influenza Vaccine

Route of administration - Intranasal spray
Type of vaccine - Live virus
Recommended groups - Healthy persons 5–49 years of age,a including health care providers and household contacts of high-risk persons
Specific high-risk indications for vaccination - Avoid in high-risk persons

”

References

↑ Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826–1831. PMID 8411526
↑ Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(RR-4):1–28. PMID 10366138.
↑ Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in adults.Cochrane Database Syst Rev. 2004;(3):CD001169. PMID 15266442
↑ Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336–1343PMID 10536125
↑ Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG (2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083. Retrieved 2012-09-06. Unknown parameter |month= ignored (help)

[butler-1] Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826–1831. PMID 8411526

[CDC-2] Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(RR-4):1–28. PMID 10366138.

[jefferson-3] Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in adults.Cochrane Database Syst Rev. 2004;(3):CD001169. PMID 15266442

[hayden-4] Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336–1343PMID 10536125

[pmid17278083-5] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG (2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083. Retrieved 2012-09-06. Unknown parameter |month= ignored (help)

[1]

[2]

[3]

[4]

[5]